In a recent study, similar histological features were seen in patients after CO2 laser treatment vs sham treatment.
According to a recent study published in the American Journal of Obstetrics & Gynecology, fractional CO2 laser and sham treatment have a similar histologic effect on vaginal tissue.
Over 60% of women experience postmenopausal vaginal symptoms which may impact quality of life. Treatment options include systemic estrogen, topical estrogen, and nonhormonal vaginal lubricants and moisturizers. However, energy-based treatments such as CO2 laser have also been indicated as a treatment method for these symptoms.
To evaluate the microscopic appearances of biopsies of human vaginal epithelium after CO2 laser, investigators conducted a double-blind randomized trial. Participants included postmenopausal womenseeking treatment for vaginal symptoms such as vaginal burning, itching, or dryness, or dysuria.
Medical treatment for vaginal symptoms was seen in some participants, but none had received vaginal energy-based treatment formenopausal symptoms. Participants had to discontinue vaginal estrogen 6 months before inclusion, and those with active genital infection were excluded. Outcomes included symptom severity and Vaginal Health Index.
Intervention treatment included 3 treatments of vaginal fractional micro-ablative CO2 laser conducted at standard settings. There were 4-to-8-week gaps between treatments. To prepare for evaluations, investigators collected vaginal biopsies and placed them in 10% neutral buffered formalin, then processed and stained them with eosin and hematoxylin.
Histologic features assessed included, “morphologic features consistent with glycogen-rich squamous epithelium, extent of vascularization of the subepithelial stroma,and thickness of the basal epithelial layer.”
There were 58 postmenopausal women who received vaginal biopsy both before and after laser or sham treatment from June 2016 to August 2020. Histological features of the vaginal wall did not significantly differ in patients receiving laser treatment compared to those receiving sham treatment.
There were also no significant differences in histological category before and after treatment between groups. In subgroup analyses, results did not change based on time since menopause, type of menopause, participant age, body mass index, or duration of reproductive years.
Type 1 histologic features pretreatment were reported in 27% of the 49 postmenopausal participants, Type 2 in 22%, and Type 3 in 51%. Participants characteristics did not differ based on histologic feature type, nor did the most bothersome symptom reported.
Significant differences in the visual analog score (VAS) for overall vaginal symptoms based on histologic feature type were not reported at baseline. There were also no significant differences in VAS for the most bothersome symptom.
These results indicated no significant microscopical differences in postmenopausal vaginal epithelium in patients given CO2 laser treatment vs sham treatment. Investigators recommended CO2 laser not be used clinically.
Reference
Li FG, Fuchs T, Deans R, et al.Vaginal epithelial histology before and after fractional CO2 laser in postmenopausal women: a double-blind, sham-controlled randomized trial. Am J Obstet Gynecol. 2023;229(278):278.E1-278.E9.doi:10.1016/j.ajog.2023.05.005
Tailored hormone therapy improves postoperative endometriosis outcomes
October 3rd 2024A recent study suggests that postoperative endometriosis patients experience improved quality of life through hormone therapies guided by optimizing treatment based on individual hormonal receptor profiles.
Read More
Study reports reduced SSI odds after gynecologic surgery from metronidazole and cefazolin
September 19th 2024A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries, enhancing patient outcomes.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More